SPOTLIGHT

STAY CONNECTED

LinkedIn  

STARTUP NEWS

WUXI NEWS

China Market Authorization Holder System Summit 2017 Recap

More than 300 professionals gathered at the recent China Marketing Authorization Holder (MAH) System Summit to learn from government agencies, life science research and drug development scientists, and drug development and...

WuXi Celebrates Partnerships & Innovation During BIO 2017 Cruise Around San Diego Bay

WuXi celebrated global innovation with hundreds of leaders from biotech, pharma, research institutions, and the venture capital community who attended BIO 2017 during a private cruise reception around San Diego Bay on...

WuXi NextCODE AI Points to New Therapeutic Approaches to Cardiovascular Disease and Cancer in...

We are thrilled about WuXi NextCODE's contribution of its artificial intelligence (AI) and sequencing teams to the discovery of a novel mechanism regulating how blood vessels grow. The study, 'FGF-dependent metabolic control...

WuXi AppTec Completes Acquisition of HD Biosciences

We are pleased to announce WuXi has completed the acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). Shanghai-based HD Biosciences' plate-based pharmacology and screening capability...

WuXi NextCODE Raises $75 Million in Series B Financing to Accelerate Growth of Global...

WuXi would like to congratulate WuXi NextCODE for raising $75 million in Series B financing, led by the company's current investors Temasek and Yunfeng Capital. WuXi NextCODE will focus the use of proceeds...

FDA UPDATES